- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02601482
Optimization of Interval-training in Patients With Type 2 Diabetes
A single bout of Interval-Walking (IW) exercise is superior to energy-expenditure and time-duration matched Continuous Walking (CW) exercise upon improving glycemic control. The time spend with high-intensity (fast) walking is considered to be responsible for the improvements seen, whereas the time spend with low-intensity (slow) walking is considered less important.
This study will assess if IW with maintained fast walking time duration but reduced total time duration (i.e. reduced slow walking time duration) is equally effective as IW with a normal time duration.
Subjects with type 2 diabetes will be included in a crossover, controlled study, where each subject will undergo three trials. Trials will be identical except the following interventions:
- Sixty minutes of rest (CON)
- Sixty minutes of classical interval walking (repeated cycles of 3 minutes of fast and 3 minutes of slow walking; IW-60)
- Fourty-five minutes of time-reduced interval walking (repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking; IW-45).
After the interventions subjects will undergo a standardized mixed meal tolerance test with assessment of glycemic control.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Copenhagen, Danmark, 2100
- Center for Physical Activity Research (CFAS)
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Type 2 Diabetes Mellitus
- BMI > 25
Exclusion Criteria:
- Pregnancy
- Smoking
- Contraindication to increased levels of physical activity
- Eating disorder
- Insulin dependence
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Control (CON)
No exercise intervention.
|
|
Eksperimentel: Normal Interval Walking (IW-60).
Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
|
|
Eksperimentel: Time-reduced Interval Walking (IW-45)
Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Glycemic control
Tidsramme: Within the first 4 hours after the intervention
|
Glycemic control will be assessed after each intervention.
Subjects will receive a standardized mixed meal tolerance test (MMTT), and blood glucose values will be obtained during the test.
|
Within the first 4 hours after the intervention
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Matsuda insulin sensitivity index
Tidsramme: Within the first 4 hours after the intervention
|
From the measurements of glucose and insulin during the MMTT, the Matsuda index of insulin sensitivity will be assessed.
|
Within the first 4 hours after the intervention
|
Stumvoll insulin sensitivity index
Tidsramme: Within the first 4 hours after the intervention
|
From the measurements of glucose and insulin during the MMTT, the Stumvoll index of insulin sensitivity will be assessed.
|
Within the first 4 hours after the intervention
|
Cederholm insulin sensitivity index
Tidsramme: Within the first 4 hours after the intervention
|
From the measurements of glucose and insulin during the MMTT, the Cederholm index of insulin sensitivity will be assessed.
|
Within the first 4 hours after the intervention
|
HOMA-2 insulin resistance index
Tidsramme: Within the first 4 hours after the intervention
|
From the measurements of glucose and insulin during the MMTT, the HOMA-2 index of insulin resistance will be assessed.
|
Within the first 4 hours after the intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- H-15008542 - 2
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 2
-
US Department of Veterans AffairsAmerican Diabetes AssociationAfsluttetType 2 diabetes mellitusForenede Stater
-
Dexa Medica GroupAfsluttetType-2 diabetes mellitusIndonesien
-
University Hospital Inselspital, BerneAfsluttetType 2 diabetes mellitusSchweiz
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Afsluttet
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Ikke rekrutterer endnuT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (Type 2 Diabetes Mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiAfsluttet
Kliniske forsøg med CON
-
University of ReadingAfsluttetFedme | Kardiovaskulær sygdom | Type 2 diabetes mellitusDet Forenede Kongerige
-
Università degli Studi di TrentoRekruttering
-
University of Southern DenmarkTeam DenmarkAfsluttet
-
Chang Gung Memorial HospitalAfsluttetCerebrovaskulær ulykkeTaiwan
-
Joseph DonnellyAfsluttetFedme | IntelligensForenede Stater
-
Biointegrator LLCAfsluttetLymfom, follikulært | Lymfom, Non-HodgkinDen Russiske Føderation
-
University of SevilleRekrutteringInsulinvækstfaktor I mangel | IGF1 mangel | Executive Function DisorderSpanien
-
Woebot HealthAfsluttet
-
Brigham and Women's HospitalThe Gillian Reny Stepping Strong Center for Trauma Innovation; Gillette...AfsluttetTraumatisk blødningForenede Stater
-
Tulane UniversityNational Institute of General Medical Sciences (NIGMS)Rekruttering